Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iloprost · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Iloprost (Ventavis inhaled, BAYQ6256) | DRUG | 2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.) |
Inclusion Criteria: * Male or female subjects aged 18 to 75 years * Symptomatic Pulmonary Artery Hypertension (PAH) classified (Dana Point Classification 1) * New York Heart Association (NYHA)/World Health Organization (WHO) functional class III or IV * PAPmean at rest \> 25 mm Hg, Pulmonary capill...
Iloprost is an inhaled small molecule developed for pulmonary hypertension, a condition of high blood pressure in the lung arteries. It is given by inhalation as Ventavis. Bayer AG is developing it, and the program has reached Phase 3 clinical development for this cardiovascular indication.
Iloprost acts as an agonist at PTGIR, the prostacyclin receptor. By activating this receptor, it mimics the effects of natural prostacyclin, a signaling molecule involved in the pulmonary vasculature. This receptor agonist activity is the basis for its use in pulmonary hypertension.
Iloprost is developed by Bayer AG, which trades under the ticker BAYRY. The inhaled formulation is known as Ventavis. Bayer is the company behind the clinical development program for this small molecule in pulmonary hypertension.
Iloprost is in Phase 3 clinical development for pulmonary hypertension. It is an investigational small molecule and has not been described as approved in this program. The Phase 3 study supporting this stage has been completed.
Iloprost has been studied in the Phase 3 trial NCT01469169, titled Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study. That trial enrolled 27 participants in Japan, included adults 18 years and older of all sexes, and has been completed.
Yes, Ventavis is the inhaled brand name for iloprost, and the compound is also referenced as BAYQ6256. Searches for Ventavis inhaled or BAYQ6256 refer to the same small molecule developed by Bayer AG for pulmonary hypertension.